All 123 patients had a flare of OA at baseline, according to the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and received celecoxib 200 mg once daily for 7 days.

Recent research indicates that colon cancer patients with circulating tumor DNA post-surgery may improve their survival likelihood with daily celecoxib use. Celecoxib, a COX-2 inhibitor, significantly ...

A data analysis from a randomized clinical trial for stage 3 colon cancer patients by investigators at Dana-Farber Brigham ...

The study group received a single 400 mg dose of celecoxib, one hour before surgery, and 200 mg of celecoxib every 12 hours for five days, along with patient-controlled analgesic (PCA) morphine.

Nearly a decade after reports first surfaced linking the prescription pain reliever celecoxib (Celebrex) to an increased risk of heart attack, and two years after the American Heart Association ...

The analysis showed that patients with positive blood tests for circulating tumor DNA (ctDNA) had worse outcomes in general, but those who were treated with celecoxib, a non-steroidal anti ...

In our study, we found that perioperative administration of celecoxib, a selective COX-2 inhibitor, reduced postoperative VAS pain scores at rest and decreased morphine usage while providing ...